1
|
Martínez-Velilla N, Arrazubi V, Zambom-Ferraresi F, Morilla-Ruiz I, Sáez de Asteasu ML, Ramírez-Vélez R, De la Casa-Marín A, Ollo-Martínez I, Gorospe-García I, Gurruchaga-Sotés I, Galbete A, Cedeño-Veloz BA, Martín-Nevado L, Izquierdo M, Vera R. Erratum to: Tailored Prevention of Functional Decline through a Multicomponent Exercise Program in Hospitalized Oncogeriatric Patients: Study Protocol for a Randomized Clinical Trial. J Nutr Health Aging 2023; 27:1287. [PMID: 38242605 DOI: 10.1007/s12603-023-2033-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2024]
Affiliation(s)
- Nicolas Martínez-Velilla
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Geriatric Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain; Department of Geriatric Medicine, Hospital Universitario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.
| | - V Arrazubi
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| | - F Zambom-Ferraresi
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Public University of Navarra, Pamplona, Spain
| | - I Morilla-Ruiz
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| | - M L Sáez de Asteasu
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Public University of Navarra, Pamplona, Spain
| | - R Ramírez-Vélez
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Public University of Navarra, Pamplona, Spain
| | - A De la Casa-Marín
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain
| | - I Ollo-Martínez
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain
| | - I Gorospe-García
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| | - I Gurruchaga-Sotés
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| | - A Galbete
- Public University of Navarra, Pamplona, Spain
| | - B A Cedeño-Veloz
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Geriatric Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain
| | - L Martín-Nevado
- Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| | - M Izquierdo
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain; Public University of Navarra, Pamplona, Spain
| | - R Vera
- IdiSNA, Navarrabiomed, Hospital Universitario de Navarra (HUN)-Universidad P blica de Navarra (UPNA), Pamplona, Spain; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain
| |
Collapse
|
2
|
Martínez-Velilla N, Arrazubi V, Zambom-Ferraresi F, Morilla-Ruiz I, Sáez de Asteasuu ML, Ramírez-Vélez R, Zambom-Ferraresi F, De la Casa-Marín A, Ollo-Martínez I, Gorospe-García I, Gurruchaga-Sotés I, Galbete A, Cedeño-Veloz BA, Martín-Nevado L, Izquierdo M, Vera R. Tailored Prevention of Functional Decline through a Multicomponent Exercise Program in Hospitalized Oncogeriatric Patients: Study Protocol for a Randomized Clinical Trial. J Nutr Health Aging 2023; 27:911-918. [PMID: 37960915 DOI: 10.1007/s12603-023-1977-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 07/31/2023] [Indexed: 11/15/2023]
Abstract
BACKGROUND Cancer mostly affects older adults, causing a wide variety of diagnostic and therapeutic dilemmas. One of the most important moments in cancer patients is the hospitalization period, in which older patients usually remain bedridden for many hours and this may lead to the appearance of sarcopenia and disability. METHODS We present the research protocol for a randomized controlled trial that will analyze whether an intervention applied to older patients (≥ 65 years) who are hospitalized for acute medical conditions in an Oncology Department improves function. A total of 240 hospitalized older patients will be recruited in the Hospital Universitario de Navarra, Pamplona, Spain, and they will be randomized. The intervention consists of a multicomponent exercise training program that will take place for 4 consecutive days (2 sessions/day). The control group will receive usual hospital care, which will include physical rehabilitation when needed. The primary end point will be the change in functional capacity from baseline to hospital discharge, assessed with the Short Physical Performance Battery (SPPB). Secondary end points will be changes in cognitive and mood status, quality of life, fatigue, strength (dynamic and handgrip), pain, nutrition, length of stay, falls, readmission rate and mortality at 3 months after discharge. RESULTS Basal data of the patients included in the RCT are described. The foreseen recruitment will not be achieved due to the context of the Covid pandemic and the significantly different responses observed during the clinical trial in oncogeriatric patients compared to our previous experience in older adults hospitalized for medical reasons. DISCUSSION If our hypothesis is correct and shows that a multicomponent, individualized and progressive exercise program is an effective therapy for improving the capacity of acutely hospitalized older patients compared to usual care, a change in the current system of hospitalization may be justified in oncogeriatric patients.
Collapse
Affiliation(s)
- N Martínez-Velilla
- Nicolas Martínez-Velilla, PhD, Department of Geriatric Medicine, Hospital Universitario de Navarra, Irunlarrea 3, 31008 Pamplona, Spain, , Twitter: @martinezvelilla
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Arraras J, Illarramendi J, Manterola-Burgaleta A, de la Cruz S, Zarandona U, Ibañez B, Salgado E, Visus I, Barrado M, Teijeira L, Martinez E, Vera R. Quality of Life of breast cancer patients with COVID-19 disease. Eur J Cancer 2022. [PMCID: PMC9671787 DOI: 10.1016/s0959-8049(22)01515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- J.I. Arraras
- Servicio Navarro de Salud/Complejo Hospitalario de Navarra, Oncology Departments, Pamplona, Spain
| | - J.J. Illarramendi
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | | | - S. de la Cruz
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - U. Zarandona
- Hospital Universitario de Navarra, Oncology Departments, Pamplona, Spain
| | - B. Ibañez
- Navarrabiomed- Departamento de Salud-UPNA, Methodology, Pamplona, Spain
| | - E. Salgado
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - I. Visus
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - M. Barrado
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - L. Teijeira
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - E. Martinez
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - R. Vera
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| |
Collapse
|
4
|
Arasanz H, Bocanegra Gondan A, Teijeira L, Garnica M, Morilla Ruiz I, Chocarro L, Martínez-Aguillo M, Ausin K, Blanco E, Zuazo M, Fernandez-Hinojal G, Echaide M, Fernández-Rubio L, Pineiro-Hermida S, Ramos P, Fernández-Irigoyen J, Kochan G, Vera R, Escors D. 1074P Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, Bocanegra A, Echaide M, Garnica M, Ramos P, Fernández-Hinojal G, Vera R, Kochan G, Escors D. Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol 2022; 14:100079. [PMID: 35755891 PMCID: PMC9216443 DOI: 10.1016/j.iotech.2022.100079] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development. In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities. Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed. LAG-3 is a highly important next-generation immune checkpoint molecule. Ninety-seven clinical trials are evaluating at least 16 LAG-3-targeting molecules. Here we identify preclinical and clinical studies conducted involving LAG-3. Bispecific LAG-3 molecules are being developed, showing strong capacities. LAG-3/PD-1 co-blockade is demonstrating encouraging results.
Collapse
Affiliation(s)
- L Chocarro
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - E Blanco
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain
| | - H Arasanz
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - L Fernández-Rubio
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - A Bocanegra
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - M Echaide
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - M Garnica
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - P Ramos
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - G Fernández-Hinojal
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - R Vera
- Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - G Kochan
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - D Escors
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| |
Collapse
|
6
|
Leonardi MS, Krmpotic C, Barbeito C, Soto F, Loza CM, Vera R, Negrete J. I've got you under my skin: inflammatory response to elephant seal's lice. Med Vet Entomol 2021; 35:658-662. [PMID: 34268793 DOI: 10.1111/mve.12538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 05/24/2021] [Accepted: 06/16/2021] [Indexed: 06/13/2023]
Abstract
Seals (Phocidae) undergo an annual cycle of moulting that implies hair regeneration, and in the case of southern elephant seals, it also involves the superficial strata of the epidermis. Therefore, surviving the moulting period is crucial for their obligate and permanent ectoparasites. Throughout evolutionary time, sucking lice (Echinophtiriidae) have developed morphological, behavioural and ecological adaptations to cope with the amphibious lifestyle of their hosts. Lepidophthirus macrorhini, the Southern elephant seal louse species, faces the additional challenge of surviving attached to the host during the moulting period. Since lice live on the skin, L. macrorhini has developed a unique survival strategy by piercing the skin of their host, thus keeping them protected from moulting. During fieldwork in Patagonia and Antarctica, skin samples with lice within were collected for histological analysis to assess whether these parasites caused damage to the host. Lice generate an inflammatory process in the host's dermis, and these lesions could alter the normal chemical and mechanical protective properties of the skin facilitating secondary infections. Further studies that analyse the potential pathogens in those skin lesions are necessary to properly assess the real impact of ectoparasites on their host health.
Collapse
Affiliation(s)
- M S Leonardi
- Instituto de Biología de Organismos Marinos, CCT CONICET CENPAT, Puerto Madryn, Argentina
| | - C Krmpotic
- Laboratorio de Morfología Evolutiva y Desarrollo (MORPHOS) y División Paleontología Vertebrados, Museo de La Plata, Fac. Cs. Naturales y Museo, UNLP, La Plata, Argentina
- CONICET, Consejo Nacional de Investigaciones Científicas y Técnicas, Puerto Madryn, Argentina
| | - C Barbeito
- CONICET, Consejo Nacional de Investigaciones Científicas y Técnicas, Puerto Madryn, Argentina
- Histología y Embriología Descriptiva, Experimental y Comparada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina
| | - F Soto
- Instituto de Biología de Organismos Marinos, CCT CONICET CENPAT, Puerto Madryn, Argentina
| | - C M Loza
- Laboratorio de Morfología Evolutiva y Desarrollo (MORPHOS) y División Paleontología Vertebrados, Museo de La Plata, Fac. Cs. Naturales y Museo, UNLP, La Plata, Argentina
- CONICET, Consejo Nacional de Investigaciones Científicas y Técnicas, Puerto Madryn, Argentina
| | - R Vera
- CCT CONICET CENPAT, Puerto Madryn, Argentina
| | - J Negrete
- Departamento de Biología de Predadores Tope, Instituto Antártico Argentino, Buenos Aires, Argentina
| |
Collapse
|
7
|
Chocarro L, Blanco E, Arasanz H, Bocanegra A, Fernández-Rubio L, Echaide M, Garnica M, Ramos P, Fernández-Hinojal G, Vera R, Kochan G, Escors D. 55P Clinical landscape of LAG-3-targeted therapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2051] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Zuazo M, Arasanz H, Chocarro L, Gondan AB, Martínez-Aguillo M, Ruiz IM, Teijeira L, Guerrero D, Nova L, Zudaire T, Arriola M, Patiño-Garcia A, Pío R, Kochan G, Escors D, Vera R. 1354P Comparison of different hyperprogressive disease criteria in non-small cell lung cancer patients treated with immunotherapy and correlation with somatic mutations in driver genes. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Aparicio J, Manrique AV, Capdevila J, Boza FM, Galván P, Richart P, Oliveres H, Paez D, Hernando J, Serrano SG, Vera R, Hernandez X, Gallego RA, Riesco-Martinez M, García de Albeniz X, Maurel J. 416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Palmeiro E, Ibañez M, Hernández C, Chocarro L, Arasanz H, Bocanegra A, Fernandez J, Santamaria E, Vera R, Smerdou C, Escors D, Kochan G. 24P The STAT3 phosphorylation status discriminates tumor associated populations in myeloid cell tumor-infiltrating model. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Arasanz H, Gondan AB, Palmeiro E, Zuazo M, Ruiz IM, Martínez-Aguillo M, Teijeira L, Fernández-Hinojal G, Chocarro L, Sancho PM, Escors D, Vera R, Kochan G. 1305P Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Chocarro L, Palmeiro E, Arasanz H, Bocanegra A, Zuazo M, Echaide M, Morente P, Fernández-Rubio L, Fernández-Hinojal G, Garnica M, Ramos P, García-Granda M, Vera R, Kochan G, Escors D. 17P PD-1 and LAG-3 immune checkpoints constitutive activators exhibit differential expression phenotypes. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Jiménez-Labaig P, Pacheco-Barcia V, Cebrià A, Gálvez F, Obispo B, Páez D, Quílez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sánchez DA, Sánchez-Cánovas M, Sanz-García E, Sesma A, Tarazona N, Cotés A, González E, Bosch-Barrera J, Fernández A, Felip E, Vera R, Rodríguez-Lescure Á, Élez E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open 2021; 6:100215. [PMID: 34325108 PMCID: PMC8332651 DOI: 10.1016/j.esmoop.2021.100215] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 06/07/2021] [Accepted: 06/25/2021] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Young oncologists are at particular risk of professional burnout, and this could have a significant impact on their health and care of their patients. The coronavirus disease 2019 (COVID-19) pandemic has forced rapid changes in professionals' jobs and training, with the consequent physical and psychological effects. We aimed to characterize burnout levels and determinants in young oncologists, and the effects of the pandemic on their training and health. METHODS Two online surveys were conducted among oncology residents and young oncology specialists in Spain. The first addressed professional burnout and its determinants before the COVID-19 pandemic, while the second analyzed the impact of the pandemic on health care organization, training, and physical and psychological health in the same population. RESULTS In total, 243 respondents completed the first survey, and 263 the second; 25.1% reported significant levels of professional burnout. Burnout was more common among medical oncology residents (28.2%), mainly in their second year of training. It was significantly associated with a poor work-life balance, inadequate vacation time, and the burnout score. Nearly three-quarters of respondents (72%) were reassigned to COVID-19 care and 84.3% of residents missed part of their training rotations. Overall, 17.2% of this population reported that they had contracted COVID-19, 37.3% had scores indicating anxiety, and 30.4% moderate to severe depression. Almost a quarter of young oncologists (23.3%) had doubts about their medical vocation. CONCLUSIONS Burnout affects a considerable number of young oncologists. The COVID-19 pandemic has had a profound impact on causes of burnout, making it even more necessary to periodically monitor it to define appropriate detection and prevention strategies.
Collapse
Affiliation(s)
- P Jiménez-Labaig
- Department of Medical Oncology, Cruces University Hospital, Barakaldo, Bizkaia, Spain
| | - V Pacheco-Barcia
- Department of Medical Oncology, Gómez Ulla Military Hospital, Madrid, Spain
| | - A Cebrià
- Department of Mental Health, Parc Taulí University Hospital, Sabadell, Catalunya, Spain
| | - F Gálvez
- Department of Medical Oncology, Jaén University Hospital, Jaén, Andalucía, Spain
| | - B Obispo
- Department of Medical Oncology, Infanta Leonor University Hospital, Madrid, Spain
| | - D Páez
- Department of Medical Oncology, Santa Creu i Sant Pau University Hospital, Barcelona, Catalunya, Spain
| | - A Quílez
- Department of Medical Oncology, Can Misses Hospital, Área de salud de Ibiza y Formentera (ASEF), Ibiza, Illes Balears, Spain
| | - T Quintanar
- Department of Medical Oncology, Elche University General Hospital, Elche, Comunitat Valenciana, Spain
| | - A Ramchandani
- Department of Medical Oncology, University Hospital Complex, Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, Islas Canarias, Spain
| | - J Remon
- Department of Medical Oncology, HM Delfos Hospital, Barcelona, Catalunya, Spain
| | - J Rogado
- Department of Medical Oncology, Infanta Leonor University Hospital, Madrid, Spain
| | - D A Sánchez
- Department of Medical Oncology, Virgen de La Arrixaca University Hospital, Murcia, Región de Murcia, Spain
| | - M Sánchez-Cánovas
- Department of Hematology and Medical Oncology, Morales Meseguer University General Hospital, Murcia, Región de Murcia, Spain
| | - E Sanz-García
- Department of Medical Oncology, HM Sanchinarro Hospital-Centro Integral Oncológico Clara Campal (CIOOC), Madrid, Spain
| | - A Sesma
- Department of Medical Oncology, Lozano Blesa University Clinical Hospital, Zaragoza, Aragón, Spain
| | - N Tarazona
- Department of Medical Oncology, INCLIVA Biomedical Research Institute, Comunitat Valenciana, Spain; Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
| | - A Cotés
- Department of Medical Oncology, Elda General Hospital, Elda, Comunitat Valenciana, Spain
| | - E González
- Department of Medical Oncology, Virgen de las Nieves University Hospital, Granada, Andalucía, Spain
| | - J Bosch-Barrera
- Department of Medical Oncology, Dr. Josep Trueta University Hospital, Institut Català d'Oncologia (ICO), Girona, Catalunya, Spain
| | - A Fernández
- Department of Medical Oncology, University Hospital Complex of Ourense (CHUO), Ourense, Galicia, Spain
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital & Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, Barcelona, Catalunya, Spain
| | - R Vera
- Department of Medical Oncology, University Hospital Complex of Navarra, Pamplona, Navarra, Spain
| | - Á Rodríguez-Lescure
- Department of Medical Oncology, Elche University General Hospital, Elche, Comunitat Valenciana, Spain
| | - E Élez
- Department of Medical Oncology, Vall d'Hebron University Hospital & Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, Barcelona, Catalunya, Spain.
| |
Collapse
|
14
|
Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM, Pazo-Cid R, Vera R, Carrato A, Feliu J. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol 2021; 23:988-1000. [PMID: 33660222 PMCID: PMC8058005 DOI: 10.1007/s12094-021-02573-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/10/2021] [Indexed: 11/10/2022]
Abstract
Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3-4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC.
Collapse
Affiliation(s)
- Mª A. Gómez-España
- Medical Oncology Department, Hospital Universitario Reina Sofía, IMIBIC, CIBERONC, Córdoba, Spain
| | - A. F. Montes
- Medical Oncology Department, Complexo Hospitalario Universitario de Ourense (CHUO), Orense, Spain
| | - R. Garcia-Carbonero
- Medical Oncology Department, Hospital Universitario, UCM, CNIO, CIBERONC, 12 de Octubre, IIS imas12, Madrid, Spain
| | - T. M. Mercadé
- Medical Oncology Department, Hospital Universitari Vall D´Hebron, Barcelona, Spain
| | - J. Maurel
- Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain
| | - A. M. Martín
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - R. Pazo-Cid
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - R. Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - A. Carrato
- Medical Oncology Department, Hospital Universitario Ramón Y Cajal, Alcala University, IRYCIS, CIBERONC, Madrid, Spain
| | - J. Feliu
- Medical Oncology Department, Hospital Universitario La Paz, CIBERONC, IDIPAZ, Madrid, Spain
| |
Collapse
|
15
|
Elez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, González Del Alba A, González Flores E, Hidalgo J, Isla D, Majem M, Rodríguez Lescure Á, Safont MJ, Santaballa A, Villacampa G, Vera R, Garrido P. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open 2021; 6:100048. [PMID: 33556897 PMCID: PMC7872979 DOI: 10.1016/j.esmoop.2021.100048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Revised: 12/22/2020] [Accepted: 12/23/2020] [Indexed: 11/20/2022] Open
Abstract
Background Women represent an increasing proportion of the oncology workforce; however, globally this does not translate into leadership roles, reflecting disparities in career opportunities between men and women. The Spanish Society of Medical Oncology (SEOM) undertook a survey to investigate gender disparity in the Spanish oncology context. Design An online survey was made available to SEOM medical oncologists between February and May 2019. It included demographics, professional context and achievements, parenthood and family conciliation issues, workplace gender bias, and approaches to address disparities. Results Of the 316 eligible respondents, 71.5% were women, 59.5% were aged 45 or younger, and 66.1% had children. Among women, 12.4% were division or unit heads, compared with 45.5% of men, with most women (74.3%) being attending medical oncologists, compared with 45.5% of men. More males were professors (34.4% versus 14.2% of females), had a PhD (46.7% versus 28.8%), and/or had led clinical research groups (41.1% versus 9.7%). Spending time overseas after completing a residency was also more common for men than women (34.4% versus 20.4%). Professional satisfaction was similar between genders, driven primarily by patient care and intellectual stimulation. More women (40.7%) considered parenthood to have a strong negative impact on their career, compared with men (9.0%). Main perceived barriers to gender equality included a lack of work–life balance (72.6% women, 44.4% men), bias of peers and superiors (50.0% women, 18.9% men), and different career goals (41.2% women, 24.4% men). Preferred solutions included educational programs and scholarships (52.9%), communication and leadership training (35.8%), childcare at conferences (33.2%), and postmaternity return-to-work incentives (32.0%). Conclusion There is a clear paucity of equal opportunities for female oncologists in Spain. This can be addressed by encouraging professional development and merit recognition particularly for younger female oncologists, and empowering women to be involved in management and leadership of institutions and professional societies. Under-representation of women in leadership roles in oncology is a widely acknowledged issue receiving global attention. This study is a national description of leadership and educational opportunities in terms of gender and family circumstances. Perceptions of gender bias in the workplace gender inequality or family conciliation issues and are described. Initiatives for equal opportunities in oncology are needed supporting female academic career development and recognition.
Collapse
Affiliation(s)
- E Elez
- Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, Barcelona, Spain
| | - F Ayala
- Hospital Universitario Morales Meseguer, Murcia, Spain
| | - E Felip
- Hospital Universitario Vall D'Hebron, Barcelona, Spain
| | | | | | - J García Donás
- Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain
| | | | | | - J Hidalgo
- Hospital Lluis Alcanyís de Xativa, Valencia, Spain
| | - D Isla
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - M Majem
- Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | | | - M J Safont
- Consorcio Hospital General Universitario, Valencia, Spain
| | - A Santaballa
- Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - G Villacampa
- Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, Barcelona, Spain
| | - R Vera
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - P Garrido
- Hospital Universitario Ramón y Cajal, Madrid, Spain.
| |
Collapse
|
16
|
Arasanz H, Zuazo M, Chocarro L, Bocanegra Gondan A, Martínez-Aguillo M, Morilla I, Fernández-Hinojal G, Blanco E, Teijeira L, Morente P, Pedroarena I, Vera R, Kochan G, Escors D. 8P Immune cell subsets in peripheral blood are associated with primary resistance to immunotherapy as frontline treatment in NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
17
|
Chocarro L, García Granda M, Zuazo M, Arasanz H, Bocanegra A, Blanco E, Hernández Sáez C, Fernández Hinojal G, Vera R, Kochan G, Escors D. 17P Engineering and expression of constitutive activators of the PD-1 and LAG-3 signaling pathways. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
Vera R, Salgado M, Safont MJ, Gallego J, González E, Élez E, Aranda E. Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clin Transl Oncol 2020; 23:827-839. [PMID: 32789773 PMCID: PMC7979622 DOI: 10.1007/s12094-020-02475-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 08/03/2020] [Indexed: 01/05/2023]
Abstract
Objective To provide guidance for the management of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in daily practice. Methods Nominal group and Delphi techniques were used. A steering committee of seven experts analyzed the current management of RAS wt mCRC, through which they identified controversies, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a group of 30 experts (the expert panel) was selected to test agreement with the statements, through two Delphi rounds. The following response categories were established in both rounds: 1 = totally agree, 2 = basically agree, 3 = basically disagree, 4 = totally disagree. Agreement was defined if ≥ 75% of answers were in categories 1 and 2 (consensus with the agreement) or 3 and 4 (consensus with the disagreement). Results Overall, 71 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) tumor location; (3) triplets; (4) maintenance; (5) second-line and beyond treatments; (6) Rechallenge and liquid biopsy. After the two Delphi rounds, only six statements maintained a lack of clear consensus. Conclusions This document aims to describe the expert’s attitude when dealing with several common clinical questions regarding patients with RAS wt mCRC. Electronic supplementary material The online version of this article (10.1007/s12094-020-02475-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Salgado
- Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - M J Safont
- Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain
| | - J Gallego
- Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain
| | - E González
- Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - E Élez
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - E Aranda
- Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Hospital Reina Sofía, University of Córdoba, Av. Menendez Pidal, s/n, 14004, Córdoba, Spain.
| |
Collapse
|
19
|
Grothey A, Tabernero J, Taieb J, Yaeger R, Yoshino T, Maiello E, Fernandez EE, Casado AR, Ross P, André T, Kato T, Ruffinelli J, Graham J, den Eynde MV, Vera R, Jean B, Roussel EC, Cahuzac C, Issiakhem Z, Vedovato J, Cutsem EV. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.080] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Borja IG, Irigoyen JF, Goñi S, Ghanem I, Amat I, Arrazubi V, Sanz JP, Hernandez-Garcia I, Vera R, Feliu J, Viudez A. P-252 Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
21
|
García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020; 22:1976-1991. [PMID: 32418154 PMCID: PMC7505870 DOI: 10.1007/s12094-020-02357-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 04/28/2020] [Indexed: 12/16/2022]
Abstract
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination of KRAS, NRAS and BRAF mutations and the convenience of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From the pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters, and its prognostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical management of patients with CRC is also outlined. All these aspects are developed in this guide, which, like the previous one, will remain open to any necessary revision in the future.
Collapse
Affiliation(s)
- P García-Alfonso
- Departament of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - R García-Carbonero
- Departament of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain
| | - J García-Foncillas
- Departament of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - P Pérez-Segura
- Departament of Medical Oncology, Hospital Clínico Universitario San Carlos, CIBERONC, Madrid, Spain
| | - R Salazar
- Departament of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain
| | - R Vera
- Departament of Medical Oncology, Complejo Hospitalario de Navarra; Navarrabiomed, IDISNA, Pamplona, Spain
| | - S Ramón Y Cajal
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - J Hernández-Losa
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - S Landolfi
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - E Musulén
- Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Vallès, Spain.,Cancer Epigenetics Group, Institut de Recerca Contra La Leucèmia Josep Carreras, Badalona, Spain
| | - M Cuatrecasas
- Department of Pathology, Hospital Clinic, CIBERehd, Barcelona, Spain
| | - S Navarro
- Department of Pathology, University of Valencia, Hospital Clínico Universitario de Valencia, CIBERONC, Valencia, Spain
| |
Collapse
|
22
|
Anticó E, Fontàs C, Vera R, Mostazo G, Salvadó V, Guasch H. A novel Cyphos IL 104-based polymer inclusion membrane (PIM) probe to mimic biofilm zinc accumulation. Sci Total Environ 2020; 715:136938. [PMID: 32032989 DOI: 10.1016/j.scitotenv.2020.136938] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 01/17/2020] [Accepted: 01/24/2020] [Indexed: 06/10/2023]
Abstract
The presence of Zn in surface waters from abandoned mining zones is a critical issue since excess Zn concentrations may affect aquatic life and whole ecosystems. We present, for the first time, a simple tool based on a polymer inclusion membrane (PIM) intended to monitor Zn in river water by mimicking metal accumulation in the biofilm. The PIM-based probe contains a polymeric membrane prepared using cellulose triacetate (CTA, 50% w/w) as the base polymer, nitrophenyloctyl ether (NPOE) as the plasticizer (20% w/w), and the ionic liquid (IL) Cyphos 104 as the extractant (30% w/w). The accumulation of Zn in the acceptor phase (0.01 M HNO3) was evaluated for different free metal concentrations at 4 h accumulation time resulting in a good correlation between the free metal concentration and the accumulated one. We also found that the metal accumulated agrees with the free metal fraction upon addition of EDTA in the donor solution. The results for Zn accumulation with the PIM-based probe were found to be comparable to those obtained for a biofilm that was grown in a stream from an abandoned mine area and subsequently translocated to the laboratory and put in contact with Zn polluted stream water, so confirming the effectiveness of this new probe in mimicking Zn accumulation in the biofilm.
Collapse
Affiliation(s)
- E Anticó
- Department of Chemistry, University of Girona, E-17003 Girona, Spain.
| | - C Fontàs
- Department of Chemistry, University of Girona, E-17003 Girona, Spain
| | - R Vera
- Department of Chemistry, University of Girona, E-17003 Girona, Spain
| | - G Mostazo
- Department of Chemistry, University of Girona, E-17003 Girona, Spain
| | - V Salvadó
- Department of Chemistry, University of Girona, E-17003 Girona, Spain
| | - H Guasch
- Department of Environmental Sciences, University of Girona, E-17003 Girona, Spain
| |
Collapse
|
23
|
Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020; 22:1963-1975. [PMID: 32318964 PMCID: PMC7505812 DOI: 10.1007/s12094-020-02350-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 04/01/2020] [Indexed: 12/14/2022]
Abstract
Pancreatic cancer (PC) remains one of the most aggressive tumors with an increasing incidence rate and reduced survival. Although surgical resection is the only potentially curative treatment for PC, only 15–20% of patients are resectable at diagnosis. To select the most appropriate treatment and thus improve outcomes, the diagnostic and therapeutic strategy for each patient with PC should be discussed within a multidisciplinary expert team. Clinical decision-making should be evidence-based, considering the staging of the tumor, the performance status and preferences of the patient. The aim of this guideline is to provide practical and evidence-based recommendations for the management of PC.
Collapse
Affiliation(s)
- E Martin-Perez
- Department of Surgery, Hospital Universitario de La Princesa, Diego de Leon 62, 28006, Madrid, Spain.
| | - J E Domínguez-Muñoz
- Department of Gastroenterology and Hepatology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - F Botella-Romero
- Department of Endocrinology, Hospital General Universitario, Albacete, Spain
| | - L Cerezo
- Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain
| | - F Matute Teresa
- Department of Radiology, Hospital Clínico San Carlos, Madrid, Spain
| | - T Serrano
- Department of Pathology, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.,Oncology Program, CIBEREHD National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Madrid, Spain
| | - R Vera
- Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain
| |
Collapse
|
24
|
Remon J, García-Campelo R, de Álava E, Vera R, Rodríguez-Peralto JL, Rodríguez-Lescure Á, Bellosillo B, Garrido P, Rojo F, Álvarez-Alegret R. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2020; 22:961-962. [PMID: 32030654 PMCID: PMC7919771 DOI: 10.1007/s12094-020-02313-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The article Liquid biopsy in oncology.
Collapse
Affiliation(s)
- J Remon
- Department of Medical Oncology, Centro Integral Oncológico Clara Campal Barcelona (CIOCCB), HM Delfos, Barcelona, Spain.
| | - R García-Campelo
- Department of Medical Oncology, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - E de Álava
- Institute of Biomedicine of Sevilla (IBiS), Department of Normal and Pathological Cytology and Histology, Virgen del Rocio University Hospital /CSIC/University of Sevilla, Sevilla, Spain.,CIBERONC, Madrid, Spain
| | - R Vera
- Department of Medical Oncology, Complejo Hospitalario de Navarra and Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - J L Rodríguez-Peralto
- CIBERONC, Madrid, Spain.,Department of Pathology, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - Á Rodríguez-Lescure
- Department of Medical Oncology, Hospital General Universitario de Elche y Vega Baja, Elche, Spain.,Group for Breast Cancer Research (GEICAM), Madrid, Spain
| | - B Bellosillo
- CIBERONC, Madrid, Spain.,Department of Pathology, Hospital del Mar, Barcelona, Spain
| | - P Garrido
- CIBERONC, Madrid, Spain.,School of Medicine, Universidad de Alcalá, Madrid, Spain.,Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - F Rojo
- CIBERONC, Madrid, Spain.,Department of Pathology, Fundación Universitaria Jiménez Díaz, Madrid, Spain
| | - R Álvarez-Alegret
- Department of Pathology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| |
Collapse
|
25
|
Arasanz H, Zuazo M, Aguillo MM, Marín BH, Fernández-Hinojal G, Bocanegra A, Ruiz IM, Gato-Cañas M, Teijeira L, Sala P, García-Granda M, Vera R, Kochan G, Escors D. A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Vera R, Aparicio J, Carballo F, Esteva M, González-Flores E, Santianes J, Santolaya F, Fernández-Cebrián JM. Correction to: Recommendations for follow‑up of colorectal cancer survivors. Clin Transl Oncol 2019; 21:1440. [DOI: 10.1007/s12094-019-02088-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Zuazo M, Arasanz H, Granda MJG, Bocanegra A, Fernández-Hinojal G, Gato-Cañas M, Aguillo MM, Marín BH, Teijeira L, Ruiz IM, Vera R, Kochan G, Escors D. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Arasanz H, Zuazo M, Santamaría E, Bocanegra A, Gato-Cañas M, Fernández-Hinojal G, Hernández-Saez C, Fernández-Irigoyen J, Santamaria E, Rodríguez-Ortigosa C, Kochan G, Vera R, Escors D. Adaption of pancreatic cancer cells to AKT1 inhibition induces the acquisition of cancer stem-cell like phenotype through upregulation of mitochondrial functions. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Vera R, González-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ, Orcajo Rincón J, Morillo Macías V, Gomez Braco MA, Suarez-Artacho G. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol 2019; 22:647-662. [PMID: 31359336 DOI: 10.1007/s12094-019-02182-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 07/08/2019] [Indexed: 12/12/2022]
Abstract
Colorectal cancer (CRC) has the second-highest tumor incidence and is a leading cause of death by cancer. Nearly 20% of patients with CRC will have metastases at the time of diagnosis, and more than 50% of patients with CRC develop metastatic disease during the course of their disease. A group of experts from the Spanish Society of Medical Oncology, the Spanish Association of Surgeons, the Spanish Society of Radiation Oncology, the Spanish Society of Vascular and Interventional Radiology, and the Spanish Society of Nuclear Medicine and Molecular Imaging met to discuss and provide a multidisciplinary consensus on the management of liver metastases in patients with CRC. The group defined the different scenarios in which the disease can present: fit or unfit patients with resectable liver metastases, patients with potential resectable liver metastases, and patients with unresectable liver metastases. Within each scenario, the different strategies and therapeutic approaches are discussed.
Collapse
Affiliation(s)
- R Vera
- Medical Oncology, Complejo Hospitalario de Navarra, Calle Irunlarrea, 3, 31008, Pamplona, Navarra, Spain.
| | | | - C Rubio
- Radiation Oncology Department, University Hospital HM Sanchinarro, Madrid, Spain
| | - J Urbano
- Vascular and Interventional Radiology, Vithas Hospitals Group, Madrid, Spain
| | - M Valero Camps
- Nuclear Medicine, Clínica Rotger (Quiron Salud), Palma de Mallorca, Spain
| | - J J Ciampi-Dopazo
- Interventional Radiology Unit, Complejo Hospitalario de Toledo, Toledo, Spain
| | - J Orcajo Rincón
- Nuclear Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - V Morillo Macías
- Radiation Oncology, Hospital Provincial de Castellón, Castellón, Spain
| | - M A Gomez Braco
- Hepatobiliary and Liver Transplantation Unit, University Hospital Virgen del Rocío, Sevilla, Spain
| | - G Suarez-Artacho
- Hepatobiliary and Liver Transplantation Unit, University Hospital Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
30
|
Aparicio J, Virgili A, Capdevila J, Muñoz Boza F, Álvarez R, Bosch C, Cámara J, Fernandez-Martos C, Fernandez-Plana J, Gallego J, Gallego R, Hernández-Yagüe X, Macías Declara I, Rodríguez-Salas N, Vera R, Taberner M, Maurel J. Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Arraras JI, Illarramendi JJ, Manterola A, Asin G, Salgado E, Arrondo P, Dominguez MA, Arrazubi V, Martinez E, Viudez A, de la Cruz S, Vera R. Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study. Clin Transl Oncol 2019; 21:1231-1239. [PMID: 30712234 DOI: 10.1007/s12094-019-02048-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Accepted: 01/16/2019] [Indexed: 11/25/2022]
Abstract
PURPOSE In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly patients treated with ET are needed. Our aims are to study QoL in early-stage breast cancer patients throughout the treatment period and compare the QoL of ET groups. METHODS 148 patients > 65 years who began ET with either tamoxifen or aromatase inhibitor (AI) completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) questionnaires three times over 3 years of ET. Linear mixed-effect models were used to evaluate longitudinal QoL changes. ET group comparisons were conducted after 3 years of treatment via ANCOVA adjusted by basal QoL. RESULTS QoL scores were high (> 80/100 points) in most QoL areas, with moderate limitations (> 30) in sexual functioning and enjoyment and in future perspective. After 3 years of ET, four QoL areas improved (< 6 points) compared to baseline and 3-month assessments. Hot flushes worsened (8 points) at the 3-month assessment but by 3 years had recovered. AI patients showed more hot flushes, pain and diarrhea and less sexual enjoyment than tamoxifen patients after 3 years of ET (differences 3-12 points). CONCLUSIONS Results indicate that elderly early-stage breast cancer patients adapted well to their disease and ET treatment over the 3 years. Few QoL differences were observed between ET groups.
Collapse
Affiliation(s)
- J I Arraras
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain. .,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.
| | - J J Illarramendi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Manterola
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - G Asin
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Salgado
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - P Arrondo
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - M A Dominguez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - V Arrazubi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Martinez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Viudez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - S de la Cruz
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| |
Collapse
|
32
|
Masjuan J, Salido L, DeFelipe A, Hernández‐Antolín R, Fernández‐Golfín C, Cruz‐Culebras A, Matute C, Vera R, Pérez‐Torre P, Zamorano JL. Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke. Eur J Neurol 2019; 26:816-820. [DOI: 10.1111/ene.13894] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 12/17/2018] [Indexed: 11/30/2022]
Affiliation(s)
- J. Masjuan
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - L. Salido
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Cardiology Department Hospital Universitario Ramón y Cajal Madrid
- CIBER CV Madrid Spain
| | - A. DeFelipe
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - R. Hernández‐Antolín
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Cardiology Department Hospital Universitario Ramón y Cajal Madrid
- CIBER CV Madrid Spain
| | - C. Fernández‐Golfín
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Cardiology Department Hospital Universitario Ramón y Cajal Madrid
- CIBER CV Madrid Spain
| | - A. Cruz‐Culebras
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - C. Matute
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - R. Vera
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - P. Pérez‐Torre
- Neurology Department Hospital Universitario Ramón y Cajal Madrid
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Invictus Plus Red Nacional de Investigación en Ictus Madrid
| | - J. L. Zamorano
- Departamento de Medicina Facultad de Medicina Universidad de Alcalá (IRYCIS) Madrid
- Cardiology Department Hospital Universitario Ramón y Cajal Madrid
- CIBER CV Madrid Spain
| |
Collapse
|
33
|
Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol 2018; 21:46-54. [PMID: 30565083 PMCID: PMC6339676 DOI: 10.1007/s12094-018-02002-w] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 11/28/2018] [Indexed: 12/22/2022]
Abstract
Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. The optimal treatment strategy for patients with metastatic CRC should be discussed in a multidisciplinary expert team to select the most appropriate treatment, and integrate systemic treatment and other options such as surgery and ablative techniques depending on the characteristics of the tumour, the patient and the location of the disease and metastases.
Collapse
Affiliation(s)
- M A Gómez-España
- Servicio de Oncología Médica, H. Universitario Reina Sofía, IMIBIC, CIBERONC, Av. Menéndez Pidal, s/n, 14004, Córdoba, Spain.
| | - J Gallego
- Servicio de Oncología Médica, Hospital General Universitario, Elche, Spain
| | - E González-Flores
- Servicio de Oncología Médica, H. U. Virgen de las Nieves, Granada, Spain
| | - J Maurel
- Servicio de Oncología Médica, Hospital Clinic, Barcelona, Spain
| | - D Páez
- Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Sastre
- Servicio de Oncología Médica, Hospital Clínico San Carlos, IdISSC, CIBERONC, Madrid, Spain
| | - J Aparicio
- Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M Benavides
- Servicio de Oncología Médica, H.U. Regional y Virgen de la Victoria, Málaga, Spain
| | - J Feliu
- Servicio de Oncología Médica, H. U. La Paz, UAM, CIBERONC, Madrid, Spain
| | - R Vera
- Servicio de Oncología Médica, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| |
Collapse
|
34
|
Vera R, Otero MJ, Ayala de la Peña F, González-Pérez C, Peñuelas Á, Sepúlveda JM, Quer N, Doménech-Climent N, Virizuela JA, Beorlegui P, Gorgas MQ. Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients. Clin Transl Oncol 2018; 21:467-478. [DOI: 10.1007/s12094-018-1945-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 09/05/2018] [Indexed: 10/28/2022]
|
35
|
Mata Velasco E, González-Flores E, Juez Martel I, Alonso V, Iranzo Gomez P, Martinez Lago N, Lopez C, Cabrera Romero J, Safont Aguilera M, Ruiz Casado A, Salgado Fernandez M, González Astorga B, Escudero P, Rivera Herrero F, Pericay Pijaume C, Vera R. In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Arasanz H, Gato-Cañas M, Zuazo M, Ibáñez-Vea M, Fernández-Hinojal G, Fernandez-Irigoyen J, Santamaria E, Kochan G, Vera R, Escors D. Isoform-specific AKT inhibition differentially affects cell functions in pancreatic adenocarcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy268.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Zuazo M, Arasanz H, Gato-Cañas M, Fernández-Hinojal G, Hernández-Marín B, Martínez-Aguillo M, Ibáñez-Vea M, Lecumberri Biurrun M, Fernández de Lascoiti Á, Vera R, Kochan G, Escors D. Pre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung cancer and correlates with risk of hyperprogression. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Ghanem I, Viudez A, García-Torralba E, Torres-Tenor J, Carmona A, Vera R, Rodriguez-Salas N, de la Peña FA, Higuera O, Feliu J. Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA. Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI). Tumori 2018; 82:554-9. [PMID: 9061063 DOI: 10.1177/030089169608200608] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background Several reports on prognostic factors for infiltrating bladder cancer have given controversial results. We assessed the prognostic value of p53 nuclear overexpression together with known prognostic factors for survival in patients with invasive T2-4 NO MO bladder cancer treated with neoadjuvant chemotherapy. Study Design Thirty-five paraffi-nized tumor samples from initial transurethral resection of patients with bladder cancer were analyzed immunohistochemi-cally to detect overexpression of p53 protein. Patients were treated with 3 to 4 cycles of neoadjuvant methotrexate, carboplatin, and vinblastine (M-CAVI) and then underwent radical cystectomy. Prechemotherapy, treatment, and postchemotherapy factors were analyzed for correlation with survival by univariate and multivariate analysis. Fifty-seven percent of tumors were positive for p53 protein, 71.5% had grade III-IV tumors, and 72% had organ-confined disease. The median follow-up was 20 months (range 5-71+). Results By univariate analysis, the significant pretreatment factors were initial tumor (T) stage ( P <0.0001) and the male sex ( P = 0.03). Five postchemotherapy variables were found significant: surgery performed according to protocol ( P = 0.003), overall clinical ( P = 0.004), and overall pathologic ( P = 0.02) response to therapy, postchemotherapy pathologic stage ( P = 0.0002), and tumor status after surgery ( P = 0.0006). By multivariate analysis, the initial prechemotherapy T stage was the only factor that demonstrated independent significance. Conclusions Although the median follow-up of the study is still too short, in this group of patients treated with a neoadjuvant carboplatin-based regimen, a classical variable (prechemotherapy T stage) rather than p53 nuclear overexpression was an independent prognostic factor for survival. Further follow-up will be required to assess the value of p53 overexpression as a prognostic factor in invasive bladder cancer patients treated with neoadjuvant carboplatin-based chemotherapy.
Collapse
Affiliation(s)
- A Ribas
- Medical Oncology Section, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Arraras J, Manterola A, Illarramendi J, Asin G, Salgado E, De la Cruz S, Ibañez B, Vera R, Dominguez M. EP-1265: Quality of Life in long term premenopausic early stages breast cancer survivors. QL determinants. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31575-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
41
|
|
42
|
Vera R, Gómez M, Ayuso J, Figueras J, Garcia-Alfonso P, Martinez V, Lacasta A, Ruiz A, Safont M, Aparicio J, Campos J, Cámara J, Martin M, Montagut C, Pericay C, Viéitez J, Falcó E, Jorge M, Marín Vera M, Salgado Fernandez M. Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Grande Pulido E, Teule A, Alonso-Gordoa T, Jiménez-Fonseca P, Benavent M, Capdevila J, Custodio A, Vera R, Munarriz J, La Casta-Muñoa A, Garcia-Carbonero R. A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Arasanz H, Zuazo-Ibarra M, Gato-Cañas M, Ibáñez-Vea M, Fernández-Hinojal G, Fernández-Irigoyen J, Santamaria E, Kochan G, Vera R, Escors D. Isoform-specific functions in pancreatic adenocarcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez P, Quintero G, Llorca C, Cañabate M, López L, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sánchez M, Gallego J, Guillén C. Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Hidalgo M, Pazo-Cid R, Guillen-Ponce C, López R, Vera R, Reboredo M, Muñoz A, Martinez de Castro E, Díaz Beveridge R, La Casta A, Martin-Valades J, Cubillo A, Martínez-Galán J, Ales I, Sastre J, Macarulla Mercade T. A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol 2017. [DOI: 10.1177/1010428317705509] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Affiliation(s)
- Estela Pineda
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Salud
- Department of Medical Oncology, Arnau de Vilanova Hospital, Lleida, Spain
| | - E Vila-Navarro
- Department of Gastrointestinal and Pancreatic Oncology, CIBERehd-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Clínic Hospital, Barcelona, Spain
| | - MJ Safont
- Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain
| | - Beatriz Llorente
- Department of Medical Oncology, Hospital Universitario de Burgos, Spain
| | - J Aparicio
- Department of Medical Oncology, La Fe University Hospital, Valencia, Spain
| | - R Vera
- Department of Medical Oncology, De Navarra Hospital, Pamplona, Spain
| | - P Escudero
- Department of Medical Oncology, Lozano Blesa Hospital, Zaragoza, Spain
| | - E Casado
- Department of Medical Oncology, Infanta Sofía Hospital, Madrid, Spain
| | - C Bosch
- Department of Medical Oncology, Pesset Hospital, Valencia, Spain
| | - U Bohn
- Department of Medical Oncology, Doctor Negrin University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - R Pérez-Carrión
- Department of Medical Oncology, Hospital Universitario Quirón Madrid, Madrid, Spain
| | - A Carmona
- Department of Medical Oncology, Morales Meseguer University Hospital, Murcia, Spain
| | - JR Ayuso
- Department of Radiology, Hospital Clinic of Barcelona, Barcelona, Spain
| | - T Ripollés
- Department of Radiology, Pesset Hospital, Valencia, Spain
| | - R Bouzas
- Department of Radiology, Hospital Alvaro Cunqueiro, Vigo, Spain
| | - M Gironella
- Department of Gastrointestinal and Pancreatic Oncology, CIBERehd-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Clínic Hospital, Barcelona, Spain
| | - X García-Albéniz
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - J Feliu
- Department of Medical Oncology, La Paz University Hospital, Madrid, Spain
| | - J Maurel
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
| |
Collapse
|
48
|
Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017; 19:667-681. [PMID: 27995549 PMCID: PMC5427095 DOI: 10.1007/s12094-016-1594-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 11/24/2016] [Indexed: 12/12/2022]
Abstract
The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.
Collapse
Affiliation(s)
- M Hidalgo
- Spanish National Cancer Centre, C/Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
- Beth Israel Deaconess Medical Center, Boston, USA.
| | - R Álvarez
- Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - J Gallego
- University Hospital of Elche, Elche, Spain
| | - C Guillén-Ponce
- Hospital Universitario Ramón y Cajal, Ctra. de Colmenar Viejo km. 9,100, 28034, Madrid, Spain
| | - B Laquente
- Institut Català d´Oncologia, Duran y Reynals Hospital, Hospitalet Llobregat, Barcelona, Spain
| | - T Macarulla
- Vall d'Hebrón University Hospital, Barcelona, Spain
| | - A Muñoz
- University Hospital Gregorio Marañón, Madrid, Spain
| | - M Salgado
- University Hospital of Ourense, Ourense, Spain
| | - R Vera
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - J Adeva
- University Hospital 12 de Octubre, Madrid, Spain
| | - I Alés
- Hospital Carlos Haya, Málaga, Spain
| | - S Arévalo
- University Hospital Donostia, San Sebastián, Spain
| | - J Blázquez
- Department of Radiology, University Hospital Ramón y Cajal, Madrid, Spain
- MD Anderson Hospital, Madrid, Spain
| | - A Calsina
- Department of Palliative Care, Hospital Germans Trias I Pujol, Institut Catalá d´Oncologia, Badalona, Spain
| | - A Carmona
- Department of Medical Oncology and Hematology, University Hospital Morales Messeguer, Murcia, Spain
| | - E de Madaria
- Department of Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain
| | - R Díaz
- Department of Medical Oncology, Hospital Universitari I Politècnic La Fe, Valencia, Spain
| | - L Díez
- Department of Surgery, Hospital Clínico San Carlos, Madrid, Spain
| | - T Fernández
- Department of Medical Oncology, Hospital Son Llàtzer, Palma de Mallorca, Spain
| | | | - M E Gallardo
- Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - I González
- Complejo Hospitalario de Granada, Granada, Spain
| | - O Hernando
- Department of Radiotherapy, University Hospital HM Sanchinarro, Madrid, Spain
- University Hospital HM Puerta del Sur, Madrid, Spain
| | - P Jiménez
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Asturias, Spain
| | - A López
- Hospital Universitario de Burgos, Burgos, Spain
| | - C López
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - F López-Ríos
- Department of Pathology, University Hospital HM Sanchinarro, Madrid, Spain
| | - E Martín
- Department of Surgery, Hospital Universitario de la Princesa, Madrid, Spain
| | - J Martínez
- Department of Medical Oncology, University Hospital Virgen de las Nieves, Granada, Spain
| | | | - J Montans
- Department of Pathology, Centro Anatomopatológico, Madrid, Spain
| | - R Pazo
- Department of Medical Oncology, University Hospital Miguel Servet, Saragossa, Spain
| | - J C Plaza
- Department of Pathology, University Hospital HM Sanchinarro, Madrid, Spain
| | - I Peiró
- Department of Endocrinology, Instituto Catalán de Oncología, Hospital Duran I Reynals, Hospitalet de Llobregat, Barcelona, Spain
| | - J J Reina
- Department of Medical Oncology, University Hospital Virgen de la Macarena, Seville, Spain
| | - A Sanjuanbenito
- Department of Surgery, University Hospital Ramón y Cajal, Madrid, Spain
| | - R Yaya
- Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| | - Alfredo Carrato
- Hospital Universitario Ramón y Cajal, Ctra. de Colmenar Viejo km. 9,100, 28034, Madrid, Spain.
| |
Collapse
|
49
|
Vera R, Fontàs C, Anticó E. Titanium dioxide solid phase for inorganic species adsorption and determination: the case of arsenic. Environ Sci Pollut Res Int 2017; 24:10939-10948. [PMID: 27655617 DOI: 10.1007/s11356-016-7667-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Accepted: 09/09/2016] [Indexed: 06/06/2023]
Abstract
We have evaluated a new titanium dioxide (Adsorbsia As600) for the adsorption of both inorganic As (V) and As (III) species. In order to characterize the sorbent, batch experiments were undertaken to determine the capacities of As (III) and As (V) at pH 7.3, which were found to be 0.21 and 0.14 mmol g-1, respectively. Elution of adsorbed species was only possible using basic solutions, and arsenic desorbed under batch conditions was 50 % when 60 mg of loaded titanium dioxide was treated with 0.5 M NaOH solution. Moreover, its use as a sorbent for solid-phase extraction and preconcentration of arsenic species from well waters has been investigated, without any previous pretreatment of the sample. Solid-phase extraction was implemented by packing several minicolumns with Adsorbsia As600. The method has been validated showing good accuracy and precision. Acceptable recoveries were obtained when spiked waters at 100-200 μg L-1 were measured. The presence of major anions commonly found in waters did not affect arsenic adsoption, and only silicate at 100 mg L-1 level severely competed with arsenic species to bind to the material. Finally, the measured concentrations in water samples containing arsenic from the Pyrinees (Catalonia, Spain) showed good agreement with the ICP-MS results.
Collapse
Affiliation(s)
- R Vera
- Department of Chemistry, University of Girona, Campus Montilivi, 17003, Girona, Spain
| | - C Fontàs
- Department of Chemistry, University of Girona, Campus Montilivi, 17003, Girona, Spain
| | - E Anticó
- Department of Chemistry, University of Girona, Campus Montilivi, 17003, Girona, Spain.
| |
Collapse
|
50
|
Rivera F, Andres R, Felip E, Garcia-Campelo R, Lianes P, Llombart A, Piera JM, Puente J, Rodriguez CA, Vera R, Virizuela JA, Martin M, Garrido P. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. Clin Transl Oncol 2017; 19:508-518. [PMID: 28005259 PMCID: PMC5346109 DOI: 10.1007/s12094-016-1595-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 09/23/2016] [Indexed: 11/29/2022]
Abstract
PURPOSE The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them. METHODS The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board. RESULTS A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035. CONCLUSIONS Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologist's workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure.
Collapse
Affiliation(s)
- F Rivera
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
- Sociedad Española de Oncología Médica (SEOM), C/ Velázquez, 7-3º planta, 28001, Madrid, Spain.
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain.
| | - R Andres
- Medical Oncology Department, Hospital Clínico Lozano Blesa, Zaragoza, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - E Felip
- Institut d'Oncologia, Vall d'Hebron University Hospital, Barcelona, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - R Garcia-Campelo
- Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Coruña, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - P Lianes
- Medical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - A Llombart
- Medical Oncology Department, Hospital Universitàri Arnau de Vilanova, Lleida, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J M Piera
- Medical Oncology Department, University Hospital Donostia, Donostia/San Sebastián, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J Puente
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
- SEOM Future Plan Advisory Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - C A Rodriguez
- Medical Oncology Department, Hospital Clínico Universitario, Salamanca, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - J A Virizuela
- Medical Oncology Department, Complejo Hospitalario Regional Virgen Macarena, Sevilla, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - M Martin
- Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 2015-2017 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| | - P Garrido
- Department of Medical Oncology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 2013-2015 SEOM Executive Board, C/ Velázquez, 7-3º planta, 28001, Madrid, Spain
| |
Collapse
|